Common variable immunodeficiency (CVID) is the most frequent symptomatic primary immunodeficiency disease, and its prevalence varies significantly among different population. Minority of CVID patients present a familial aggregation suggesting a higher probability of heritable genetic defects. A total of 235 registered CVID patients were evaluated in this cohort study. Familial and sporadic patients were stratified, and demographic information, clinical records, laboratory and molecular data were compared among these two groups of patients. Multiple cases were identified in 12 families (30 patients) and sporadic presentation in 120 cases. The rate of parental consanguinity (83.3%) and clinical presentation of lymphoid malignancy (20.7%) were predominant in familial CVID patients, whereas significantly increased recurrent upper respiratory infections were recorded in sporadic patients (0.3 infections per year). Probands of familial group were presented with a higher severity score resulting in a profound mortality rate (41.7% after 30-year follow-up) comparing to the nonproband CVID patients in the same families with a lowered diagnostic delay. Familial CVID patients had a specific signature in clinical presentation and immunologic profile, and a high consanguinity in this group of patients suggests a Mendelian trait with an autosomal recessive inheritance pattern. Diagnosis of an index patient within a multiple case families significantly improves the diagnostic process and outcomes of the yet asymptomatic patients.
Introduction
Common variable immunodeficiency (CVID) is a heterogeneous group of primary immunodeficiency diseases (PID) with an estimated prevalence of 1:50,000-1:20,000 [1] . CVID patients are susceptible to recurrent pyogenic infections and manifest different non-infectious clinical phenotypes including gastrointestinal problems, lymphoproliferative disorders, autoimmunity and allergic diseases [2] [3] [4] [5] . Symptoms of recurrent infection can start at any time of life, but there are peaks of onset during 1-5 and 16-20 years of age [6, 7] . Mortality rate in the first 10 years after diagnosis ranges from 10 to 35% in CVID patients [7] [8] [9] , and the most common cause of death is a respiratory failure [10, 11] . The effectiveness of intravenous immunoglobulin (IVIg) treatment for decreasing chronic infections in patients with CVID is well documented [12, 13] .
In addition to genetic defects, including CD19, CD20, CD21, CD81, CD27, CD70, LRBA, CTLA-4, ICOS, IL-21, IL-21R, NFKB1, NFKB2, RAC2, PIK3R1, PIK3CD and TWEAK deficiencies [14] [15] [16] , some immunologic defects in the innate and adaptive immune systems have been also identified to underlie CVID disease [17] [18] [19] [20] [21] ; however, the exact pathogenesis of CVID remains unclear yet. Only 10-20% of cases are familial with a predominance of a Mendelian inheritance, while 90% of them are sporadic [7, 8, 22] , commonly resulting from a complex interaction of environmental and genetic factors (multifactorial inheritance).
Family history of other types of primary immunodeficiency has been reported in the relatives of CVID cases including selective IgA deficiency (SIgAD) and subclass IgG deficiency [23, 24] . Moreover some of familiar cases of SIgAD have been reported that gradually progress to CVID [25, 26] . Furthermore, it has been identified that family members of CVID patients appear to have an increased risk of other immune-related disorders particularly malignancy and autoimmunity [16, 27, 28] .
In this study, we compare two groups of sporadic versus familial patients, from different aspects, including clinical manifestations, severity of complications, laboratory and immunologic data in a high consanguinity and early onset cohort of CVID patients to clarify common features and specify differentiations of these two groups.
Patients and methods
Patients. A total number of 235 patients whom were diagnosed as CVID at Children's Medical Center (Pediatrics Center of Excellence affiliated to Tehran University of Medical Sciences, Tehran, Iran) and were registered in national primary immunodeficiency network database were evaluated [9, 29] . The patients with incomplete family history and pedigree data were excluded. The inclusion criteria for patients are defined by the European Society of Immune Deficiencies (ESID) and the Pan American Group for Immune Deficiency (PAGID) which includes reduction in at least two serum Ig isotypes (IgG, IgA and/or IgM) by two standard deviations from normal mean values for age, and exclusion of other causes of hypogammaglobulinemia in individuals aged >4 years, evidence of specific antibody deficiency and no evidence of profound T cell deficiency [7, 30] . We subsequently categorized patients into two groups; Group A was the patients with the familial form of the disease, meaning that the patient had at least one family member (1st degree or 2nd degree) who were diagnosed with CVID. Group B constituted the sporadic patients without any records of stillbirth, childhood death due to infections and not even unknown reason. We then matched sporadic patients with familial patients based on the duration of the disease. The process of this study was approved by the ethics committee of Tehran University of Medical Science, and an informed consent was obtained from all patients or their parents or legal guardians prior study enrolment.
Data collection, clinical phenotyping and severity scoring. A one-page questionnaire was completed for each patient to collect information such as demographic data, clinical manifestations, infectious or non-infectious complications, immunologic phenotype and mortality information. The clinical phenotype of each patient was assigned according to modified four phenotypes: polyclonal lymphocytic infiltration (PLI), autoimmunity, enteropathy and infections only [9, 31] . The severity of clinical presentation in each patient also was calculated using a standard scoring system described previously [24, 32] .
Statistical analysis. Statistical analysis was performed using a commercially available software package (SPSS Statistics 24.0, Chicago, IL, USA). The KolmogorovSmirnov test was performed to evaluate the normality of distribution. Parametric and nonparametric analyses were performed based on the findings of this evaluation. Kaplan-Meier curve and log-rank test were utilized to compare different survival estimates. A P-value of <0.05 was considered statistically significant.
Results
Higher rate of consanguinity and mortality in probands of familial patients A total of 120 CVID patients including 30 familial cases (from 12 distinct families) and 90 sporadic cases were enrolled in the study: 67 of them were males (55.8%), while 53 were females (44.2%). The median age of the patients was 20 (range 4-56) years. The median age at the time of diagnosis and the median diagnostic delay were 9 (range 4-38) years and 5 (range 0.1-28) years. The median duration of disease was 15.6 (range 2.2-40.4) years. The rate of parental consanguinity for all patients was 64.2%; it was recorded in 57.8% for sporadic cases while 83.3% of parents of familial cases were consanguineous (P = 0.015). At the time of the study, 26 cases (21.6%) were deceased, while 94 were alive. The mortality rate was similar among familial (six of 30, 20%) and sporadic (20 of 90, 22.2%) groups. Interestingly, 83.3% of mortality in familial group was documented in index probands (five of 12 versus one of 18, P = 0.06), which was in line with a higher delayed diagnosis (9.5 [range years in familial probands versus 6 [range 0. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] years in the rest of familial patients, P = 0.02). Consistently, the survival analysis revealed <58.3% in probands after 30-year follow-up which was significantly lower than non-probands from the same families (87.9%, P = 0.01, Fig. 1 ). The complete demographic data of patients, divided into three groups (total, sporadic and familial patients), are shown in Table 1 .
Dominancy of lymphoid malignancy in familial CVID patients
The most frequent first presentation in both groups of familial (36.7%) and sporadic (34.4%) patients was lower respiratory tract infections. Although comparison of both groups for their first presentation failed to show any significant difference, skin infection was only recorded as primary presentation in sporadic (6.7%) and autoimmunity in familial (6.7%) groups. Details regarding the clinical features of all patients and also the familial group versus the sporadic group are provided in Table 2 .
Our result showed that patients in the sporadic group suffer from a higher frequency of upper respiratory tract infections than patients in the familial group (0.34 AE 0.28 versus 0.22 AE 0.13 respectively, P = 0.008). Moreover, the patients in the sporadic group had a higher probability of manifesting skin infections during the course of the disease (24.4%) compared to the familial group (7.4%), but this association was not significant (P = 0.06). Similar to family group, we observed a significant reverse correlation between organomegaly and CD4+ T cell count (P = 0.03) in sporadic group, although this correlation was not strong (r = À0.22) (Table 3) . Moreover, there was a significant reverse correlation between mortality rate with IgA) P = 0.04 (and IgM level (P = 0.02) sporadic group that were not severe (r = À0.21 and, r = À0.24, respectively) (Table 3 ). Susceptibility to malignancies particularly lymphoma was significantly increased among patients in the familial group than patients in the sporadic group (20.7% versus 4.4%, respectively, P = 0.013). Furthermore, the rate of atopic manifestations (35.7% versus 18.9%) and coeliac disease (7.4% versus 0%) was observed being more frequent within the familial CVID patients.
The severity score of clinical manifestation in familial cases was similar to patients in sporadic group (7.1 AE 3.7 versus 7.1 AE 3.0); however, this score was significantly higher in probands of familial group (10.2 AE 8.0) comparing to non-probands (5.8 AE 2.9, P = 0.002). The mean of .......................................................................................................................................................... ..... severity score was higher in patients with positive parental consanguinity than patients with negative parental consanguinity. This difference was more prominent in the familial group (6.2 AE 5.1 for the patients with negative parental consanguinity versus 7.4 AE 3.4 for the patients with positive parental consanguinity) compared with the sporadic group. Clinical phenotyping of CVID patients revealed that patients in the familial group were classified mainly in the PLI and autoimmunity clinical phenotype comparing to the sporadic patients, whereas only infectious phenotype was slightly higher in sporadic cases. Moreover, clinical phenotype was concordant in 24 of 30 familial cases (80%). Details regarding the clinical phenotypes of all patients are depicted in a Venn diagram provided in Fig. 2 .
Increased serum IgM level immunologic signature of familial CVID patients
The complete analysis results of immunologic factors of patients are shown in Table 3 . The disturbed lymphocyte subset at the time of diagnosis was slightly increased in sporadic patients as low CD4+ T cells identified in 28.9%, high CD8+ T cells in 32.5% and low CD19+ in 28.9% of these patients. Surprisingly, patients in the familial group were shown to have significantly higher levels of IgM compared to the sporadic group (38.0 AE 20.8 versus 19.0 AE 15.2, P < 0.001). The analyses failed to show any other significant difference between the two groups in terms of other immunologic factors.
Multivariate analysis within the familial CVID patients group
Higher age at the time of diagnosis was associated with more severe complications in the familial group (P = 0.041). Interestingly, a positive correlation between IgM levels and rate of pneumonia infection was observed in the familial group (P = 0.017). We also found that the mortality rate has a statistically significant correlation with the history of lymphadenopathy in familial patients (P = 0.043). The history of lymphadenopathy has a correlation with the incidence of lymphoma in familial patients (P = 0.089), although it was not statistically significant.
Our result indicated that history of splenomegaly or hepatomegaly in the familial CVID patients is associated with a higher mortality rate (P = 0.023 and P = 0.002, respectively). Among laboratory data of familial group, organomegaly had only a significant reverse correlation with CD4+ T cell count (P = 0.03, r = À0.41) ( Table 3 ). The lymphoid malignancy phenotype was also corelated with higher mortality rate in this group of patients (P = 0.038). Our results indicated that there was no correlation between degrees of familial patients with laboratory data.
Discussion
Common variable immunodeficiency (CVID) is a common group of symptomatic PID affecting humoral immunity [1] that its pathogenesis is not fully understood yet. Patients present with a wide spectrum of clinical complications. Most patients are sporadic cases with no affected family member, although in 10-20% of cases at least one affected family member has been reported [23, 24] . Thus, we tried to compare these two subgroups, using 30 cases with an affected family member age-matched with 90 sporadic cases by the duration of the disease.
Parental consanguinity is a known risk factor for monogenic PID with an autosomal recessive pattern of inheritance [22, 33, 34] . In Iran, parental consanguinity is reported in 72% of patients suffering from CVID, while the mean proportion of consanguineous marriages in the country is 38% [35] . Previously, we also showed that the rate of parental consanguinity was significantly higher in children with early onset disease than in adults [9] . Furthermore, we have shown that the rate of multiple cases in a consanguineous cohort of CVID patients is more than 30% if all first relatives without severe clinical manifestations are evaluated [36] . We found that there is more positive parental consanguinity in the familial patients compared with the sporadic ones.
Rivoisy et al. [37] indicated that positive parental consanguinity was associated with more severe clinical complications in CVID patients that was consistent with our study. We evaluated our patients' disease severity based on a scoring system suggested by Yong et al. [32] mean of severity score was higher in patients with positive parental consanguinity particularly in the familial group. This higher rate of consanguinity in familial CVID patients was associated with a severe clinical phenotype, and higher mortality rate in index patients suggests a Mendelian trait with possibility to finding a monogenic disorder in this group of patients. Our findings proved that diagnosis of an index patient within a multiple case families significantly improves the awareness of clinical immunologist for timely diagnosis and proper treatment in the second patients of the families. This can be biased the non-significant comparisons of different parameters in familial versus sporadic groups, as the second affected patients were diagnosed earlier with less severe phenotype and complications. However, stratification of the proband of these families gives a better picture about the nature of the disease and its prognosis to compare with sporadic individuals.
In our study, the familial group showed a significantly higher IgM levels at the time of diagnosis compared with the sporadic group, but the severity of the disease in both groups was not significantly different. It seems that the difference of IgM levels between two groups is not the result of individual variation as we found a positive correlation between IgM levels and rate of pneumonia infection in the familial group. This could be due to the fact that pneumonia infection is [32] . *P-value is statistically significant <0.5. Organomegaly means manifestation of splenomegaly or hepatomegaly or lymphadenopathy. For qualitative variable correlation was calculate by spearman test.
a Normal value was considered according the patients age from the following references [46, 47] . *P-value is statistically significant <0.5.
**Chi-Square test was used to determine an association.
Scandinavian Journal of Immunology, 2017, 86, 239-247 associated with a profound defect in process of class switching recombination in subgroup of familiar patients resulting to a higher level of IgM [38] . The incidence of lymphoma was higher in the familial group, while the rate of sinusitis and otitis media was higher in the sporadic group. Moreover, more patients from the familial group suffered asthma and allergy compared with the sporadic group. There are some evidence that family members of patients with CVID have an increased incidence of autoimmune disease [27, 39] . Our familial group patients showed a higher rate of autoimmune diseases compared with the sporadic group. It has been suggested that there are several overlapping mechanisms leading to the association of autoimmune responses and CVID, including increased antigen exposure, immune dysfunction inherits in CVID and genetic predisposition [27] . The clustering and co-occurrence of SIgAD and CVID within families together with the high prevalence of autoimmune diseases within these primary antibody deficiencies suggests that genetic factors play a vital role in the pathogenesis. Furthermore, our patients from the familial group were affected more than the sporadic ones with the coeliac disease. The familial association of CVID and SIgAD with autoimmune diseases and coeliac disease highlights the common pathogenic genetic cause rather than the possibility of an epigenetic and post-infectious immunopathogenetic influence. These data indicate a distinct clinical manifestation signature in the familial group versus sporadic patients encouraging prioritization of next generation sequencing in this group of patients [40] .
According to defined CVID clinical phenotypes, our familial patients showed a higher incidence of PLI with a high tendency towards the presentation of lymphoid malignancy. In a study by Resnick et al., it was expressed that higher levels of IgM were associated with increased risk of lymphoma [41] and this is compatible with our results too. These data indicate that severe clinical/ immunologic manifestations such as PLI, hyper-IgM level and malignancy, more seen in the familial group, may be classified as a separate group for searching shared genetic background [42] . As this combined phenotype was associated with a high mortality rate in index patient of the familial patients, discovering the genetic defect in this group may help a correct therapeutic strategy for managing these patients. In addition, we found that the mortality rate has a significant correlation with the history of lymphadenopathy, splenomegaly or hepatomegaly in familial patients. Among laboratory data, our results demonstrated that both familial and sporadic groups had a significant reverse correlation between organomegaly and CD4+ T cell count. Consistent with our results, Malphettes et al. indicated that reduction in CD4+ T cells is associated with the increased incidence of splenomegaly in CVID patients [43] . Decreased CD4+ T cells in CVID patients are associated with reduced thymic output [44] and increased apoptosis of naive T cells [45] . Association of splenomegaly with low CD4+ T cells could be due to increased infection and expansion of other lymphocyte subsets as compensatory mechanism.
Conclusion
Although most of CVID patients are sporadic cases, with no apparent history of the disorder in the family, it seems that there are some key features in the minority of patients ............................................................................................................................................................... with familial presentation. Familial patients have shown more parental consanguinity, higher IgM levels and an increased incidence of lymphoid malignancies. The index patients in family group manifested severe clinical manifestations compared to second patients. However, further genetic studies using next generation sequencing can reveal the possibility of monogenic aetiology in this group of patients.
